The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient&#39;s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

AFM28 - Affimed

https://ash.confex.com/ash/2024/webprogram/Paper210275.html

Nanni Schmitt1; Jana-Julia Siegler2; Alexandra Beck1; Lea Hoppe1; Mohammed Abba, MD1; Alexander Streuer, MD1; Stefan Klein, MD1; Wolf-Karsten Hofmann, MD1; Christian Merz2; Jens Pahl2; Daniel Nowak, MD1

Nov 6, 2024